Literature DB >> 18027090

Syndecan-1: a dynamic regulator of the myeloma microenvironment.

Ralph D Sanderson1, Yang Yang.   

Abstract

Emerging data in myeloma and other cancers indicates that heparan sulfate proteoglycans promote tumor progression by enhancing their growth and metastasis. By acting as key regulators of cell signaling via their interactions with multiple growth and angiogenic factors, heparan sulfates mediate a shift in the microenvironment that supports the tumor as an 'organ' and promotes an aggressive tumor phenotype. In addition, enzymatic remodeling of heparan sulfate proteoglycans provides a mechanism for rapid, localized and dynamic modulation of proteoglycan function thereby tightly regulating activities within the tumor microenvironment. New data from animal models demonstrates that heparan sulfate or the enzymes that regulate heparan sulfate are viable targets for cancer therapy. This strategy of targeting heparan sulfate may be particularly effective for attacking cancers like myeloma where extensive genetic chaos renders them unlikely to respond well to agents that target a single signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18027090      PMCID: PMC3633534          DOI: 10.1007/s10585-007-9125-3

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  128 in total

Review 1.  Specificities of heparan sulphate proteoglycans in developmental processes.

Authors:  N Perrimon; M Bernfield
Journal:  Nature       Date:  2000-04-13       Impact factor: 49.962

Review 2.  Proteoglycans and pattern formation: sugar biochemistry meets developmental genetics.

Authors:  S B Selleck
Journal:  Trends Genet       Date:  2000-05       Impact factor: 11.639

Review 3.  Functions of cell surface heparan sulfate proteoglycans.

Authors:  M Bernfield; M Götte; P W Park; O Reizes; M L Fitzgerald; J Lincecum; M Zako
Journal:  Annu Rev Biochem       Date:  1999       Impact factor: 23.643

4.  Serum syndecan-1: a new independent prognostic marker in multiple myeloma.

Authors:  C Seidel; A Sundan; M Hjorth; I Turesson; I M Dahl; N Abildgaard; A Waage; M Borset
Journal:  Blood       Date:  2000-01-15       Impact factor: 22.113

5.  CD138/syndecan-1: a useful immunohistochemical marker of normal and neoplastic plasma cells on routine trephine bone marrow biopsies.

Authors:  M Chilosi; F Adami; M Lestani; L Montagna; L Cimarosto; G Semenzato; G Pizzolo; F Menestrina
Journal:  Mod Pathol       Date:  1999-12       Impact factor: 7.842

6.  Heparan sulfate proteoglycans as extracellular docking molecules for matrilysin (matrix metalloproteinase 7).

Authors:  W H Yu; J F Woessner
Journal:  J Biol Chem       Date:  2000-02-11       Impact factor: 5.157

7.  High levels of soluble syndecan-1 in myeloma-derived bone marrow: modulation of hepatocyte growth factor activity.

Authors:  C Seidel; M Børset; O Hjertner; D Cao; N Abildgaard; H Hjorth-Hansen; R D Sanderson; A Waage; A Sundan
Journal:  Blood       Date:  2000-11-01       Impact factor: 22.113

8.  Syndecan-1 is required for Wnt-1-induced mammary tumorigenesis in mice.

Authors:  C M Alexander; F Reichsman; M T Hinkes; J Lincecum; K A Becker; S Cumberledge; M Bernfield
Journal:  Nat Genet       Date:  2000-07       Impact factor: 38.330

9.  Shedding of syndecan-1 and -4 ectodomains is regulated by multiple signaling pathways and mediated by a TIMP-3-sensitive metalloproteinase.

Authors:  M L Fitzgerald; Z Wang; P W Park; G Murphy; M Bernfield
Journal:  J Cell Biol       Date:  2000-02-21       Impact factor: 10.539

Review 10.  The elusive functions of proteoglycans: in vivo veritas.

Authors:  A D Lander; S B Selleck
Journal:  J Cell Biol       Date:  2000-01-24       Impact factor: 10.539

View more
  51 in total

1.  Heparanase-neutralizing antibodies attenuate lymphoma tumor growth and metastasis.

Authors:  Marina Weissmann; Gil Arvatz; Netanel Horowitz; Sari Feld; Inna Naroditsky; Yi Zhang; Mary Ng; Edward Hammond; Eviatar Nevo; Israel Vlodavsky; Neta Ilan
Journal:  Proc Natl Acad Sci U S A       Date:  2016-01-04       Impact factor: 11.205

Review 2.  The mutual impact of syndecan-1 and its glycosaminoglycan chains--a multivariable puzzle.

Authors:  Anna S Eriksson; Dorothe Spillmann
Journal:  J Histochem Cytochem       Date:  2012-08-16       Impact factor: 2.479

3.  Serglycin proteoglycan is required for multiple myeloma cell adhesion, in vivo growth, and vascularization.

Authors:  Anurag Purushothaman; Bryan P Toole
Journal:  J Biol Chem       Date:  2014-01-08       Impact factor: 5.157

4.  Bone metabolism markers and angiogenic cytokines as regulators of human hematopoietic stem cell mobilization.

Authors:  Pantelis Tsirkinidis; Evangelos Terpos; Georgios Boutsikas; Athanasios Papatheodorou; Konstantinos Anargyrou; Eleni Lalou; Aglaia Dimitrakopoulou; Christina Kalpadakis; Konstantinos Konstantopoulos; Marina Siakantaris; Panayiotis Panayiotidis; Gerassimos Pangalis; Marie-Christine Kyrtsonis; Theodoros Vassilakopoulos; Maria K Angelopoulou
Journal:  J Bone Miner Metab       Date:  2017-06-28       Impact factor: 2.626

5.  Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patients.

Authors:  Caroline Rousseau; Ludovic Ferrer; Stéphane Supiot; Manuel Bardiès; François Davodeau; Alain Faivre-Chauvet; Pierre Baumgartner; John Wijdenes; Marie Lacombe; Jacques Barbet; Thierry Guillaume; Philippe Moreau; Jean Luc Harousseau; Françoise Kraeber-Bodéré; Michel Cherel
Journal:  Tumour Biol       Date:  2012-03-03

6.  Heparanase Modulates Shh and Wnt3a Signaling in Human Medulloblastoma Cells.

Authors:  Lon D Ridgway; Michael D Wetzel; Dario Marchetti
Journal:  Exp Ther Med       Date:  2011-03-01       Impact factor: 2.447

Review 7.  Breast and ovarian cancers: a survey and possible roles for the cell surface heparan sulfate proteoglycans.

Authors:  Atsuko Yoneda; Maria E Lendorf; John R Couchman; Hinke A B Multhaupt
Journal:  J Histochem Cytochem       Date:  2012-01       Impact factor: 2.479

Review 8.  Non-anticoagulant heparins and inhibition of cancer.

Authors:  Benito Casu; Israel Vlodavsky; Ralph D Sanderson
Journal:  Pathophysiol Haemost Thromb       Date:  2009-01-27

9.  Syndecan-1 (CD138) Suppresses Apoptosis in Multiple Myeloma by Activating IGF1 Receptor: Prevention by SynstatinIGF1R Inhibits Tumor Growth.

Authors:  DeannaLee M Beauvais; Oisun Jung; Yang Yang; Ralph D Sanderson; Alan C Rapraeger
Journal:  Cancer Res       Date:  2016-06-30       Impact factor: 12.701

10.  XBP1 governs late events in plasma cell differentiation and is not required for antigen-specific memory B cell development.

Authors:  Derrick J Todd; Louise J McHeyzer-Williams; Czeslawa Kowal; Ann-Hwee Lee; Bruce T Volpe; Betty Diamond; Michael G McHeyzer-Williams; Laurie H Glimcher
Journal:  J Exp Med       Date:  2009-09-14       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.